# A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

> **NCT02993926** · — · COMPLETED · sponsor: **Takeda** · enrollment: 108 (actual)

## Conditions studied

- Central Precocious Puberty

## Interventions

- **DRUG:** Enantone
- **DRUG:** GnRH agonist

## Key facts

- **NCT ID:** NCT02993926
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-24
- **Primary completion:** 2018-09-30
- **Final completion:** 2018-09-30
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02993926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02993926, "A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02993926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*